← Eichor
Condition: Primary Peritoneal Cavity Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Primary Peritoneal Cavity Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemo
Phase 3 · 8 location(s) · Imunon · NCT06915025A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard o
Phase 3 · 186 location(s) · Merck Sharp & Dohme LLC · NCT06824467Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian
Phase 1 · 2 location(s) · University of Colorado, Denver · NCT06856499A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary
Phase 2 · 92 location(s) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis P · NCT05128825Determining Prognostic Immune Markers in Patients With Ovarian Cancer
Phase N/A · 1 location(s) · Leiden University Medical Center · NCT03862677Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
Phase 2 · 1 location(s) · Loyola University · NCT05983276Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Phase 3 · 59 location(s) · GOG Foundation · NCT05659381A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06994195Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05415709Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Phase N/A · 1 location(s) · Nordic Society of Gynaecological Oncology - Clinical Trials · NCT05574673APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurr
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT04919629Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Phase 1 · 2 location(s) · M.D. Anderson Cancer Center · NCT03968406Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Phase 2 · 6 location(s) · The University of Hong Kong · NCT07023484A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 79 location(s) · Artios Pharma Ltd · NCT04657068Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)
Phase 3 · 1 location(s) · Fudan University · NCT04520074Study of AVZO-021 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Avenzo Therapeutics, Inc. · NCT05867251HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06855069Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
Phase N/A · 1 location(s) · Affidea Nu-med Center of Oncological DIagnostics and Therapy · NCT07667192Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherap
Phase 2 · 9 location(s) · University of Alabama at Birmingham · NCT04606914Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Pr
Phase 1/Phase 2 · 4 location(s) · Imunon · NCT05739981Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 1/Phase 2 · 3 location(s) · Mayo Clinic · NCT05920798Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 2 · 1 location(s) · Ronald Buckanovich · NCT05538091Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal
Phase 3 · 19 location(s) · M.D. Anderson Cancer Center · NCT04575935A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.
Phase 2 · 17 location(s) · Shanghai Jiaolian Drug Research and Development Co., Ltd · NCT06434610Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gyne
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT07586826A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Phase 2 · 70 location(s) · Fore Biotherapeutics · NCT05503797A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Gr
Phase 2 · 52 location(s) · AbbVie · NCT06682988Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ova
Phase 1/Phase 2 · 52 location(s) · Regeneron Pharmaceuticals · NCT03564340A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Day One Biopharmaceuticals, Inc. · NCT05377996CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery i
Phase 1/Phase 2 · 7 location(s) · TORL Biotherapeutics, LLC · NCT07322094
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.